The DMS Group is composed of companies with a strong innovative potential. Foremost focused on the medical imaging industry, it is aimed to extend to new horizons these last few years. By orienting its strategy toward the future and investing in R&D, the Group aims to bring out tomorrow’s solutions.
DMS Group is present on all continents through a network of more than 140 national distributors, subsidiaries, and joint ventures.
DMS Group is quoted on the Euronext Growth market in Paris (ALDMS).
Specialized in high technology for medical diagnosis, DMS Imaging positions itself as the French leader in the design, development, and manufacturing of medical imaging systems dedicated to radiology, bone densitometry, and posturology.
DMS Biotech supports the group’s development strategy in the field of biotechnology, particularly in technologies for the treatment of osteoarthritis and regenerative medicine based on the injection of fat stem cells.
Publication of Q1 2023 turnover
Publication of 2022 annual results
Publication of first half 2023 turnover
Publication of 2023 semi-annual results
Publication of Q3 2023 turnover
Publication of annual turnover 2023
Publication of 2023 annual results